$SHOUGANG LANZA(02553)$ Shougang Lanze Biotechnology Co., Ltd. (HKEX: 02553) bucked the market trend with a gain of over 6%. As a leader in carbon capture, utilization, and storage (CCUS), the company is positioned to benefit from the rapid expansion of the sustainable aviation fuel (SAF) market..
$BitMine Immersion Technologies Inc.(BMNR)$ September 9th, BitMine's Board Chairman Tom Lee posted on social media that as part of BitMine's \"Lunar Landing Plan\" strategy, Bitmine (BMNR) acquired 13 million shares of OCTO at a price of $1.46 per share, with a total investment of $20 million. At the time of writing, Eightco Holdings (OCTO) surged by 4834.83% intraday, with a stock price of $71.56, an increase of $70.1 for the day. This means that Bitmine's 13 million shares of OCTO are currently worth $960 million, with a paper profit of $940 million in this OCTO investment transaction. Excerpt..waiting.. 🤑🤑🤑
Pertama Digital Malaysia 4th-Quarter 2024 Earnings Summary Table
Pertama Digital - Malaysia quarter ended Dec 31: Figures Are In Ringgit . 20242023 Revenue1,866,0001,583,000 PreTax Profit178,000692,000 Net Profit436,000255,000 Earnings Per Share0.10 Sen0.06 Sen Dividend0.00 Sen0.00 Sen 12 months ended Dec 31: Revenue6,773,0006,182,000 PreTax Profit-1,181,000-10,533,000 Net Profit-512,000-6,357,000 Earnings Per Share-0.12 Sen-1.46 Sen Dividend0.00 Sen0.00 Sen
CERo Says US FDA Clears Investigational New Drug Application to Launch Leukemia Treatment Trial; Shares Soar
CERo Therapeutics Holdings said Friday that the US Food and Drug Administration has cleared its investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.The company said it expects to start the phase 1 trial in Q1 of 2025.CERo's shares soared past 79% in recent trading.Price: 0.34, Change: +0.15, Percent Change: +79.22
A new era in mankind against deadly diseases, deserves our bullish and encouraging support. FOR ALL MANKIND
CERo Says US FDA Clears Investigational New Drug Application to Launch Leukemia Treatment Trial; Shares Soar
CERo Therapeutics Holdings said Friday that the US Food and Drug Administration has cleared its investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.The company said it expects to start the phase 1 trial in Q1 of 2025.CERo's shares soared past 79% in recent trading.Price: 0.34, Change: +0.15, Percent Change: +79.22